Immunotherapy has been the holy grail in the fight against cancer for the last decade. For good reason, we’ve been...
Read more
Now 10 years into the golden era of immuno-oncology (I-O) following the first FDA approval of ipilimumab (anti-CTLA4) in 2011…
Read more